Trial reportFrontiers in immunology2019
A Non-interventional Clinical Trial Assessing Immune Responses After Radiofrequency Ablation of Liver Metastases From Colorectal Cancer.
Open access · goldAbstract readClinical Trial
In one paragraph
Trial report in Frontiers in immunology, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 31 papers.
0numbers the graph read from it
0cells of the map it votes in
31citing papers in PubMed
2.4field-weighted citation impact, top 9% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
31 citing papers in PubMed, 41 citations in OpenAlex.
- Review
- Hepatic radiofrequency ablation induces widespread cellular activation throughout the liver.European radiology experimental · 2026Article
- Biomarker guided combination strategies and perioperative integration for immune cold microsatellite stable colorectal cancer.Discover oncology · 2026Review
- Synergistic immunomodulation: integrating physical ablation with immune checkpoint inhibitors for metastatic colorectal carcinoma.Frontiers in immunology · 2026Review
- Liver microenvironment-driven immunosuppressive niche in colorectal cancer liver metastasis and its therapeutic remodeling.Frontiers in immunology · 2026Review
- Towards a personalized utilization of stereotactic body radiotherapy for the management of liver metastases in solid tumors.Cancer metastasis reviews · 2025Review
- Logistic regression analysis of pathological features of bone metastasis in colorectal cancer and related influencing factors after surgery.World journal of gastrointestinal surgery · 2025Article
- Beyond Adaptive Immunity: Trained Innate Immune Responses as a Novel Frontier in Hepatocellular Carcinoma Therapy.Cancers · 2025Review
- Local ablative therapies and the effect on antitumor immune responses in pancreatic cancer - A review.Heliyon · 2024Review
- Threatment Strategies for Recurrent Hepatocellular Carcinoma Patients: Ablation and its Combination Patterns.Journal of Cancer · 2024Review
- Liver-Directed Therapy Combined with Systemic Therapy: Current Status and Future Directions.Seminars in interventional radiology · 2023Review
- Contrast-enhanced ultrasound guidance improves the therapeutic efficacy of radiofrequency ablation in liver cancer patients.American journal of translational research · 2023Article
- Microwave ablation combined with anti-PD-1/CTLA-4 therapy induces an antitumor immune response to renal cell carcinoma in a murine model.Cell cycle (Georgetown, Tex.) · 2023Article
- Synergic fabrication of multifunctional liposomes nanocomposites for improved radiofrequency ablation combination for liver metastasis cancer therapy.Drug delivery · 2022Article
- Article
- Comparative analysis of the immune response to RFA and cryoablation in a colon cancer mouse model.Scientific reports · 2022Article
- Synergetic Thermal Therapy for Cancer: State-of-the-Art and the Future.Bioengineering (Basel, Switzerland) · 2022Review
- Interventional oncology of liver tumors: how it all started and where are we now.The British journal of radiology · 2022Review
- CD169-positive macrophages enhance abscopal effect of radiofrequency ablation therapy in liver cancer.Translational oncology · 2022Article
- Hyperthermia combined with immune checkpoint inhibitor therapy in the treatment of primary and metastatic tumors.Frontiers in immunology · 2022Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
23 authors at 8 institutions in 1 country.
Markus W LöfflerDepartment of Immunology, Interfaculty Institute for Cell Biology, University of Tübingen, Tübingen, Germany.
Bianca NussbaumDepartment of Immunology, Interfaculty Institute for Cell Biology, University of Tübingen, Tübingen, Germany.
Günter JägerInstitute of Medical Genetics and Applied Genomics, University Hospital Tübingen, Tübingen, Germany.
Philipp S JurmeisterInstitute of Pathology, Charité - Universitätsmedizin Berlin, Berlin, Germany.
Jan BudcziesInstitute of Pathology, Charité - Universitätsmedizin Berlin, Berlin, Germany.
Philippe L PereiraDepartment of Diagnostic and Interventional Radiology, University Hospital Tübingen, Tübingen, Germany.
Stephan ClasenDepartment of Diagnostic and Interventional Radiology, University Hospital Tübingen, Tübingen, Germany.
Daniel J KowalewskiDepartment of Immunology, Interfaculty Institute for Cell Biology, University of Tübingen, Tübingen, Germany.
Lena MühlenbruchDepartment of Immunology, Interfaculty Institute for Cell Biology, University of Tübingen, Tübingen, Germany.
Ingmar KönigsrainerDepartment of General, Visceral and Transplant Surgery, University Hospital Tübingen, Tübingen, Germany.
Stefan BeckertDepartment of General, Visceral and Transplant Surgery, University Hospital Tübingen, Tübingen, Germany.
Ruth LadurnerDepartment of General, Visceral and Transplant Surgery, University Hospital Tübingen, Tübingen, Germany.
Silvia WagnerDepartment of General, Visceral and Transplant Surgery, University Hospital Tübingen, Tübingen, Germany.
Florian BullingerDepartment of Immunology, Interfaculty Institute for Cell Biology, University of Tübingen, Tübingen, Germany.
Thorben H GrossDepartment of Immunology, Interfaculty Institute for Cell Biology, University of Tübingen, Tübingen, Germany.
Christopher SchroederInstitute of Medical Genetics and Applied Genomics, University Hospital Tübingen, Tübingen, Germany.
Bence SiposInstitute of Pathology and Neuropathology, University Hospital Tübingen, Tübingen, Germany.
Alfred KönigsrainerDepartment of General, Visceral and Transplant Surgery, University Hospital Tübingen, Tübingen, Germany.
Stefan StevanovićDepartment of Immunology, Interfaculty Institute for Cell Biology, University of Tübingen, Tübingen, Germany.
Carsten DenkertInstitute of Pathology, Charité - Universitätsmedizin Berlin, Berlin, Germany.
Hans-Georg RammenseeDepartment of Immunology, Interfaculty Institute for Cell Biology, University of Tübingen, Tübingen, Germany.
Cécile GouttefangeasDepartment of Immunology, Interfaculty Institute for Cell Biology, University of Tübingen, Tübingen, Germany.
Sebastian P HaenDepartment of Immunology, Interfaculty Institute for Cell Biology, University of Tübingen, Tübingen, Germany.
University Children's Hospital Tübingen · DEUniversity of Tübingen · DEGerman Cancer Research Center · DEBernstein Center for Computational Neuroscience Tübingen · DECharité - Universitätsmedizin Berlin · DEHeidelberg University · DEPhilipps University of Marburg · DESLK-Kliniken Heilbronn · DE
Funding
No grant is acknowledged in the PubMed record.
Abstract
PubMed holds no abstract for this paper.
Indexed as
ImmunityAgedCatheter AblationChromatography, LiquidColorectal NeoplasmsComputational BiologyExome SequencingFemaleGene Expression ProfilingHLA AntigensHumansImmunophenotypingLigandsLiver NeoplasmsMaleMicrosatellite InstabilityHLA AntigensLigandsabscopal effectcolorectal cancerHLA ligandomeliver metastasisneoepitopesradiofrequency ablationT cellstumor-associated antigens
Identifiers
What OpenQuestion holds
Textmetadata
LicenceCC BY
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.